GSK343
CAS : 1346704-33-3
Ref. 3D-WDC70433
5mg | À demander | ||
10mg | À demander | ||
25mg | À demander | ||
50mg | À demander | ||
100mg | À demander |
Informations sur le produit
- 1-(1-Methylethyl)-N-[(6-methyl-2-oxo-4-propyl-1,2-dihydro-3-pyridinyl)methyl]-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide
- 1H-Indazole-4-carboxamide, N-[(1,2-dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-
- Gsk 343
- N-[(1,2-Dihydro-6-methyl-2-oxo-4-propyl-3-pyridinyl)methyl]-1-(1-methylethyl)-6-[2-(4-methyl-1-piperazinyl)-4-pyridinyl]-1H-indazole-4-carboxamide
GSK343 is a compound that inhibits the activity of histone methyltransferases. It is used in the treatment of cancer and has been shown to inhibit the growth of Hl-60 cells and 3T3-L1 preadipocytes. GSK343 also inhibits the proliferation of epithelial mesenchymal cells, which may be due to its ability to induce cell cycle arrest at G2/M phase. The inhibition of cancer cell proliferation by GSK343 has been linked to increased levels of the protein p27, which binds to cyclin D and prevents its association with CDK4 or CDK6. This results in reduced levels of cyclin E, Rb phosphorylation, and subsequent release from Rb inhibition. This leads to an increase in S phase followed by apoptosis. In addition, GSK343 has been shown to inhibit polymerase chain reaction (PCR) amplification of DNA by binding to double stranded DNA.
Propriétés chimiques
Question d’ordre technique sur : 3D-WDC70433 GSK343
Si vous souhaitez demander un devis ou passer commande, veuillez plutôt ajouter les produits souhaités à votre panier, puis demander un devis ou passer commande à partir de votre panier. C'est une méthode plus rapide, plus économique, et vous pourrez bénéficier des remises disponibles ainsi que d'autres avantages